article · Journal of Biomaterials Science Polymer Edition
Malaria remains a major global health challenge, worsened by the rise of drug-resistant <i>Plasmodium falciparum</i>. Quinine is a cornerstone therapy for severe malaria, yet its clinical use is limited by rapid clearance, dose-dependent toxicity, and a narrow therapeutic window. To address these challenges, we developed chitosan-functionalized poly(ε-caprolactone) core-shell nanoparticles (QN-PCL/CS NPs) for enhanced quinine delivery. Fabricated <i>via</i> double emulsion solvent evaporation, the nanoparticles exhibited favorable characteristics: 312.9 ± 11.7 nm diameter, +30.8 ± 1.5 mV zeta potential, and 81.8 ± 6.9% encapsulation efficiency. <i>In vitro</i> studies confirmed efficient drug incorporation and sustained biphasic release. Notably, QN-PCL/CS NPs significantly improved the therapeutic safety profile, increasing the cytotoxicity IC<sub>50</sub> in Vero cells from 131.93 µg/mL (free quinine) to 345.93 µg/mL, while enhancing antiplasmodial activity against chloroquine-resistant <i>P. falciparum</i> (FCR3 strain), lowering the IC<sub>50</sub> from 130.12 ng/mL to 32.56 ng/mL. This dual improvement resulted in an approximately ten-fold increase in the selectivity index (from 1.014 to 10.658) and a two-fold increase in quinine penetration into infected erythrocytes. Complementary <i>in silico</i> analyses revealed molecular mechanisms underlying these effects: density functional theory identified quinine's reactive sites, and molecular docking predicted strong binding to chitosan (-4.02 kcal/mol) and PCL (-3.99 kcal/mol), explaining the high encapsulation efficiency. Together, these results demonstrate that QN-PCL/CS NPs offer a promising platform for drug-resistant malaria treatment, simultaneously addressing efficacy and toxicity challenges. This integrated <i>in silico-in vitro</i> approach provides both a therapeutically enhanced nanoformulation and a mechanism-guided blueprint for rational design of polymer-based drug delivery systems.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1080/09205063.2026.2639582
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.